Researchers set out to compare radiofrequency ablation and endoscopic surveillance in Barrett's esophagus patients with low-grade dysplasia in a recent study published in the Journal of the American Medical Association.
The researchers hoped to determine whether or not radiofrequency ablation decreases the rate of neoplastic progression. The study included 136 confirmed Barrett's esophagus patients with low-grade dysplasia. Of these patients, 68 received ablation and 68 were placed in a control group.
The researchers found:
• Ablation reduced the risk of progression to high-grade dysplasia by 25 percent
• Ablation reduced the risk of progression to adenocarcinoma by 7.4 percent
• Complete dysplasia eradication occurred in 92.6 percent of the patients receiving ablation
• Complete intestinal metaplasia eradication occurred in 88.2 percent of the patients receiving ablation
• Complete dysplasia eradication occurred in 27.9 percent of the patients in the control group
• Complete intestinal metaplasia occurred in none of the patients in the control group
• Adverse events, the most common being stricture, related to treatment occurred in 19.1 percent of patients receiving ablation
The researchers concluded that radiofrequency ablation reduced the risk of neoplastic progression over three years of follow-up.
More Articles on Gastroenterology:
Advocacy in the Gastroenterology Field: Q&A With AGA President Dr. Anil Rustgi
The Most Exciting Advances in the GI Field: 9 Gastroenterologists Weigh In
AGA Members Attend White House Tour
The researchers hoped to determine whether or not radiofrequency ablation decreases the rate of neoplastic progression. The study included 136 confirmed Barrett's esophagus patients with low-grade dysplasia. Of these patients, 68 received ablation and 68 were placed in a control group.
The researchers found:
• Ablation reduced the risk of progression to high-grade dysplasia by 25 percent
• Ablation reduced the risk of progression to adenocarcinoma by 7.4 percent
• Complete dysplasia eradication occurred in 92.6 percent of the patients receiving ablation
• Complete intestinal metaplasia eradication occurred in 88.2 percent of the patients receiving ablation
• Complete dysplasia eradication occurred in 27.9 percent of the patients in the control group
• Complete intestinal metaplasia occurred in none of the patients in the control group
• Adverse events, the most common being stricture, related to treatment occurred in 19.1 percent of patients receiving ablation
The researchers concluded that radiofrequency ablation reduced the risk of neoplastic progression over three years of follow-up.
More Articles on Gastroenterology:
Advocacy in the Gastroenterology Field: Q&A With AGA President Dr. Anil Rustgi
The Most Exciting Advances in the GI Field: 9 Gastroenterologists Weigh In
AGA Members Attend White House Tour